行情

CATB

CATB

Catabasis Pharms
NASDAQ

实时行情|Nasdaq Last Sale

7.00
0.00
0.00%
休市 16:00 01/17 EST
开盘
7.10
昨收
7.00
最高
7.24
最低
7.00
成交量
22.03万
成交额
--
52周最高
9.76
52周最低
4.020
市值
8,258.03万
市盈率(TTM)
-2.6390
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CATB 新闻

  • 沪指低开低走 IMF上调2020年中国经济增长预期
  • 新浪财经.31分钟前
  • 港股异动 | 受疫情影响,九毛九盘中一度重挫超6%
  • 华盛通.2小时前
  • 韩国网上银行Kakao Bank计划上市 腾讯为第二大股东
  • IPO早知道.2小时前
  • 特朗普前往达沃斯:我们现在是宇宙第一,遥遥领先!
  • 环球网.2小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CATB 简况

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
展开

Webull提供Catabasis Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。